Abstract
The interaction between Cryptococcus neoformans and the host system is a consummate process, on account of the multiple components involved in its traversal of the blood-brain barrier (BBB). It is possible that this yeast pathogen may use different mechanisms of invasion under different physiological or pathological conditions. Understanding these mechanisms of encroachment can explicate the route of invasion, which may provide us with an indication for identifying the potential drug target sites. Current C. neoformans management still relies on the anti-fungal reagents, such as amphotericin B, fluconazole, or fluorocytosine. However, potential treatments on BBB, e.g., flurofamide and simvastatin, are emerging. This review summarizes the possible routes for C. neoformans traversal of the BBB, current regimens for C. neoformans, and potential new targets for treatments.
Keywords: Amphotericin B, brain invasion, blood-brain barrier, C. neoformans, lipid rafts, simvasatatin.
Anti-Infective Agents
Title:The Blood-Brain Barrier: Targeting in the Pathogenesis of C. neoformans Meningitis and Drug Discovery
Volume: 11 Issue: 2
Author(s): Hsiang-Kuang Tseng, Sheng-He Huang, Gregory Shackleford and Ambrose Jong
Affiliation:
Keywords: Amphotericin B, brain invasion, blood-brain barrier, C. neoformans, lipid rafts, simvasatatin.
Abstract: The interaction between Cryptococcus neoformans and the host system is a consummate process, on account of the multiple components involved in its traversal of the blood-brain barrier (BBB). It is possible that this yeast pathogen may use different mechanisms of invasion under different physiological or pathological conditions. Understanding these mechanisms of encroachment can explicate the route of invasion, which may provide us with an indication for identifying the potential drug target sites. Current C. neoformans management still relies on the anti-fungal reagents, such as amphotericin B, fluconazole, or fluorocytosine. However, potential treatments on BBB, e.g., flurofamide and simvastatin, are emerging. This review summarizes the possible routes for C. neoformans traversal of the BBB, current regimens for C. neoformans, and potential new targets for treatments.
Export Options
About this article
Cite this article as:
Tseng Hsiang-Kuang, Huang Sheng-He, Shackleford Gregory and Jong Ambrose, The Blood-Brain Barrier: Targeting in the Pathogenesis of C. neoformans Meningitis and Drug Discovery, Anti-Infective Agents 2013; 11 (2) . https://dx.doi.org/10.2174/2211352511311020005
DOI https://dx.doi.org/10.2174/2211352511311020005 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Trials for Neuroprotection in ALS
CNS & Neurological Disorders - Drug Targets Pharmacology of Adenosine A2A Receptors and Therapeutic Applications
Current Topics in Medicinal Chemistry Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories
Current Drug Safety CD93: Recent Advances and Implications in Disease
Current Drug Targets Cytokine/Antibody Complexes: An Emerging Class of Immunostimulants
Current Pharmaceutical Design Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design Prolactin and Blood-Brain Barrier Permeability
Current Neurovascular Research The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors
Current Medicinal Chemistry Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Long-Term CD4 Cell Count Recovery among Thai Naive HIV-Infected Patients Initiating HAART at Low CD4 Cell Count
Current HIV Research Production and Application of Bacteriophage and Bacteriophage-Encoded Lysins
Recent Patents on Biotechnology Integrase Strand Transfer Inhibitors and the Emergence of Immune Reconstitution Inflammatory Syndrome (IRIS)
Current HIV Research Is Ecto-nucleoside Triphosphate Diphosphohydrolase (NTPDase)-based Therapy of Central Nervous System Disorders Possible?
Mini-Reviews in Medicinal Chemistry Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Nitrergic Response to Clostridium perfringens Infection in the Rat Brain Regions Effect of Red Light Irradiation
Central Nervous System Agents in Medicinal Chemistry Gene Therapy Targeting in the Central Nervous System
Current Gene Therapy Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Treatment of Central Nervous System Involvement Associated with Primary Sjogrens Syndrome
Current Pharmaceutical Design An Association of Virus Infection with Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry